INIS
patients
100%
antibodies
96%
reviews
43%
biological markers
43%
lupus
41%
diseases
36%
levels
33%
control
27%
covid-19
25%
vaccines
24%
thrombosis
22%
vitamin d
21%
glycoproteins
21%
usa
21%
rheumatic diseases
21%
oxidation
21%
values
21%
safety
21%
cytokines
21%
inflammation
20%
tissues
16%
proteins
15%
tumor necrosis factor
15%
hands
14%
arthritis
14%
giant cells
14%
fingers
14%
comparative evaluations
12%
growth factors
12%
laboratories
11%
phospholipids
11%
morbidity
11%
pregnancy
11%
molecules
10%
adhesion
10%
skin
9%
mice
9%
data
9%
recommendations
8%
classification
8%
risks
8%
production
8%
therapy
7%
nails
7%
methotrexate
7%
demineralization
7%
glass
7%
eruption
7%
x radiation
7%
histology
7%
Keyphrases
Antiphospholipid Antibodies
50%
Non-criteria Antiphospholipid Antibodies
43%
Antibody Test
43%
Antiphospholipid Syndrome
35%
Fluvastatin
35%
13th
28%
Galveston
28%
International Congresses
28%
Meta-analysis
21%
Task Force Report
21%
Immunogenicity
21%
Multicentric Reticulohistiocytosis
21%
Rheumatic Diseases
21%
SARS-CoV-2 Vaccination
21%
Review Analysis
21%
Test Report
21%
Anti-MDA5
21%
Phospholipids
21%
Case-based Review
21%
Statins
21%
Confidence Interval
18%
Clinical Manifestations
17%
Pregnancy Morbidity
14%
Laboratory Assays
14%
Thrombosis
14%
Coagulation Cascade
14%
Autoantibodies
14%
Evidence-based
14%
Classification Criteria
14%
Seroconversion
12%
Soluble Tissue Factor
11%
Lupus Antibodies
7%
E-selectin
7%
Tumor Necrosis Factor-α
7%
Annexin A5
7%
Anticardiolipin Antibodies
7%
Texas
7%
Anticoagulant Activity
7%
Lupus Anticoagulant
7%
Cardiolipin
7%
I to
7%
Vascular Endothelial Growth Factor
7%
Clinical Trials
6%
Rituximab
6%
Vaccination
6%
Mycophenolate
6%
Obstetric Pathology
5%
Hypovitaminosis D
5%
Immunology and Microbiology
Phospholipid Antibody
55%
Force
43%
Antiphospholipid Syndrome
35%
Vaccine Efficacy
28%
COVID-19
27%
Association
24%
Systemic Lupus Erythematosus
24%
Severe Acute Respiratory Syndrome Coronavirus 2
24%
Glycoprotein
21%
MDA5
21%
Dermatomyositis
21%
Immunoglobulin A
21%
Rheumatic Disease
21%
Proinflammatory Cytokine
21%
Immunogenicity
21%
Monospecific Antibody
17%
Seroconversion
15%
Morbidity
12%
Pregnancy
12%
Classification
9%
Autoantibodies
9%
Vasculotropin
9%
Interleukin-6
9%
Lupus Erythematosus
8%
Cytokine Production
6%
Cytokine
6%
Tumor Necrosis Factor
6%
Interleukin-1
6%
Rituximab
6%
Mycophenolic Acid
6%
Cells
5%
Lung
5%
Myositis
5%